The incorporation of genomic testing to identify targetable somatic alterations and predisposing germline mutations into the clinical setting is becoming increasingly more common. Despite its potential usefulness, to the authors' knowledge physician confidence with regard to understanding and applying genomic testing remains unclear, particularly within the realm of pediatric oncology. METHODS: Before initiating an institutional feasibility study regarding the integration of clinical genomic testing, the authors surveyed pediatric oncologists regarding their confidence around understanding of genomic testing, perceived usefulness of test results, preferences around the disclosure of germline test results, and possible risks and benefits of testing. RESULTS: Among survey respondents (52 of 88 contacted; response rate of 59%), only a minority were confident in interpreting, using, and discussing somatic (35%) or germline (27%) genomic test results. Providers who were confident in interpreting somatic results were significantly more likely to anticipate using the results to plan the treatment of patients with relapsed or refractory cancers (P 5.009). Similarly, providers who reported confidence in interpreting germline results were significantly more likely to discuss and use these results as part of clinical care (P<.0001). The majority of physicians (93%), regardless of their level of confidence, wanted to speak to a genetic counselor before disclosing germline test results. CONCLUSIONS: Among physicians at a comprehensive pediatric cancer center, confidence in the interpretation, use, and discussion of oncology-based genomic test results appears to be low, both in terms of somatic and germline testing. To optimize the integration of genomic sequencing into cancer care, methods must be developed to improve basic competencies around cancer-based genomic testing. Given the complexities surrounding variant interpretation and genotype-phenotype relationships, interdisciplinary collaborations are warranted. Cancer 2017;123:2352-9.
INTRODUCTION
Next-generation sequencing approaches, including whole-exome, whole-genome, and RNA sequencing, have revolutionized our ability to analyze the genetic composition of tumor and normal tissues. It now is possible to interrogate massive amounts of genetic information at the point of testing and use this information to guide treatment decisions. 1 Although the knowledge gained from genomic sequencing has increased our understanding of disease development and treatment response, many questions remain unanswered regarding how best to integrate this technology into actual practice. [2] [3] [4] [5] [6] Currently, the scientific understanding of genotype-phenotype correlations and the predictive value of genomic data remain unclear. 7 The uncertainty that often surrounds the interpretation and usefulness of sequencing data creates challenges for health care providers as they incorporate clinical genome and exome sequencing (CGES) into patient management. Several of these challenges include: 1) understanding and interpreting CGES results; 2) determining when and if findings should be used in clinical care; and 3) developing meaningful ways to communicate genomic findings and These challenges are of particular importance in oncology, in which precision medicine and the use of targeted therapies are a major research and clinical focus. Toward this end, CGES analysis of tumor tissue is becoming increasingly common in the management of cancer as oncologists look for specific driver mutations or altered signaling pathways that are amenable to targeted therapy. 9 Given emerging data regarding the beneficial effects of cancer surveillance and risk-reducing measures, there also is interest in using germline CGES to detect underlying cancer susceptibility syndromes. 10 Genomic sequencing is a complex technology that rapidly transitioned from research-only use to application in the clinical setting. Nonetheless, to the best of our knowledge few data exist, particularly in pediatric oncology, to describe whether and how providers: 1) understand the information generated through CGES; 2) use CGES in patient management; and 3) communicate with patients regarding their results.
Prior literature indicates low levels of provider confidence in interpreting and applying results generated from focused genetic testing for mutations associated with disease risk (eg, cancer predisposition). [11] [12] [13] [14] [15] In a 1999 survey of 1251 US physicians, only 29% reported confidence in counseling patients regarding cancer susceptibility testing, although the confidence rate was somewhat higher among oncologists (50%). 12 Reasons cited for the lack of confidence were numerous, but included uncertainty regarding the availability of genetic testing practice guidelines, the clinical usefulness of test results, and the availability of testing services and health care providers to provide the necessary counseling for patients. 12 An additional study of medical oncologists' attitudes toward multiplex tumor genomic testing found that approximately 50% felt "somewhat confident" in their knowledge regarding genetics and 22% expressed "low confidence" in their ability to explain genomic concepts. 13 Across studies, genomic confidence appears to be a predictor of attitudes regarding the use of testing. The more confident and qualified the physician feels with genomics, the more likely he or she is to recommend testing. 13, 14 Factors associated with ordering cancer susceptibility testing included physicians feeling very well or somewhat qualified to recommend testing, as opposed to those who feel not very or not at all qualified to recommend testing. 10 These surveys of provider confidence largely have been limited to a general population of physicians and medical oncologists across diverse clinical settings. To our knowledge, it is not clear whether confidence and comfort with genomic sequencing are higher among pediatric oncologists practicing in a cancer center in which exposure to precision medicine initiatives may be more common. St. Jude Children's Research Hospital is a National Comprehensive Cancer Network (NCCN) facility located in Memphis, Tennessee, that accepts approximately 500 new pediatric oncology patients per year. In 2015, our institution developed a prospective study (Genomes for Kids) to assess the feasibility of integrating CGES into the care of children with cancer. As the study and studyrelated procedures and educational materials were developed, it was recognized that physician self-assurance with understanding, communicating, and using CGES results were important considerations. Therefore, before initiating Genomes for Kids, providers were surveyed regarding their confidence, knowledge, and perceived risks and benefits of CGES using tumor and germline samples from pediatric oncology patients undergoing cancer treatment at St. Jude. In addition, providers were asked about their preferences for the disclosure of test results and interest in assistance from a genetic counselor (GC). At the time of survey participation, no formal institutional sequencing protocols existed; however, oncologists were free to order germline or somatic genetic testing on an ad hoc basis in patients they suspected of having a cancer predisposing genetic condition or tumor with a potentially targetable lesion. St. Jude enrolls approximately 78 patients annually (average for 2005-2015) on early-phase (phase 1/2) research studies with only a minority of these patients requiring clinical somatic sequencing (for identification of a target lesion) for study enrollment.
MATERIALS AND METHODS

Participants
All pediatric hematology/oncology physicians with clinical responsibilities in oncology were invited to participate in a deidentified electronic survey in August 2015. This Institutional Review Board-approved survey was distributed via E-mail to 58 attending physicians and 30 hematology/oncology fellows. Informed consent was obtained by wavier and implied by survey completion.
Survey Instrument
Survey questions were developed after a review of the literature and multidisciplinary needs assessment to identify knowledge gaps and areas of current debate surrounding the integration of clinical genomics into pediatrics and pediatric oncology. The face validity of these questions was established through expert review by researchers in clinical genomics, nursing research, pediatric oncology, and bioethics. This mixed-methods survey most commonly provided response options followed by an optional box for qualitative clarification (see Supporting Information survey instrument). The survey was administered via SurveyMonkey (https://www.surveymonkey.com/), with an estimated time to completion of <15 minutes. The survey included Likert-based quantitative questions specific to clinician confidence in interpreting, discussing, and using the somatic and germline sequencing results as well as areas for qualitative responses. Physicians were queried about their preferred method of learning about information contained in somatic and germline reports and their preferences around results disclosure. The survey also elicited physician perceptions regarding their expectations for using CGES results in clinical care as well as the risks and benefits of CGES testing.
Statistical Analysis
Descriptive statistics (number and percentage) were reported for questionnaire responses. The chi-square or Fisher exact tests (for sparse data) were used to compare questionnaire responses between responder subgroups. Subgroups were defined by the type of provider (fellow vs physician) and by questionnaire responses related to confidence in knowledge of interpreting the results of somatic and germline genomic findings (nonconfident vs confident). We defined confident as a response of 4 on a 5-point scale (1 indicates not at all confident, 2 indicates not at all confident to unsure, 3 indicates unsure, 4 indicates unsure to very confident, and 5 indicates very confident). Statistical analyses were conducted with SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC). A 2-sided significance level of P<.05 was used for all statistical tests. Raw P values are reported, but were adjusted for multiple testing using the false discovery rate to ensure statistical significance.
RESULTS
Demographics
Of the 88 physicians who received the survey, 30 attending physicians and 22 fellows responded, yielding an overall response rate of 59%. Throughout the survey, there were no statistically significant differences observed in the responses between physicians and fellows. Given the small sample size, no statistical comparisons were conducted between oncologic subspecialties.
Provider Confidence
Providers were asked about confidence in 3 domains: interpreting, using, and discussing somatic and germline genomic test results (Table 1) . Approximately 50% of respondents stated a lack of confidence across all domains (48% for somatic and 52% for germline). Of the remaining respondents, 35% were confident in all 3 aspects of somatic results and 27% were confident for germline CGES. Confidence in interpreting the results of genomic results was mixed, with 23 providers (44%) reporting confidence in interpreting somatic test results and 21 (40%) reporting confidence in interpreting germline test results. A total of 46 providers (88%) were concordant in their responses regarding somatic and germline confidence with only 19 stating they were confident in interpreting both types of genomic test results and 27 stating they were not confident in interpreting either type of result. Six providers (12%) were discordant in their responses, with 4 providers confident only in interpreting somatic and 2 providers confident only in interpreting germline test results.
Responses to subsequent questions were stratified based on whether a provider was confident in interpreting somatic and germline test results. Providers who reported confidence in interpreting somatic results were significantly more likely to have confidence in discussing somatic results with their patients and using these results in patient care when compared with their colleagues who were not confident (P<.0001, respectively) ( Table 1) . Similarly, providers who reported confidence in interpreting germline results were significantly more likely to have confidence in discussing and using germline results when compared with their nonconfident colleagues (P<.0001, respectively) ( Table 1) .
GC Involvement
Provider input was elicited regarding GC involvement when disclosing germline test results (Table 2) . Responding providers (40 providers) were found to have a strong preference for GC involvement, with 37 (93%) indicating a desire to speak with a GC prior to disclosing germline test results and 27 providers (68%) indicating a preference to have a counselor present during the disclosure. Providers (40 providers) were divided with regard to their preferences around the disclosure of test results, with 14 (35%) stating they would like to be the first to convey the germline test results, 16 (40%) stating they did not wish to convey the germline test results before the patient met with a GC, and 10 (25%) stating they were unsure. Of the 14 providers indicating they wanted to convey germline test results before the patient met with a GC, 13 (93%) stated that they would like to consult a GC before disclosure of the results and 7 of 13 (54%) reported a preference to have a GC present at the time of disclosure. No significant differences were observed based on provider confidence in interpreting results. 
Perceived Usefulness of Genomic Test Results
With regard to the perceived usefulness of somatic CGES, approximately 70% of providers (28 of 40 providers) stated they would use somatic results when planning treatment for patients with refractory or recurrent disease (Table 3) . Providers who were confident in interpreting somatic test results were found to be significantly more likely than their nonconfident colleagues (P 5 .009) to state that they might use somatic test results to plan treatment of patients with refractory or recurrent disease.
Those providers who stated that they would use somatic results (28 providers) were asked follow-up questions to assess how they might use this information; 93% reported they would use results to find a new study for the patient, 93% would add a specific drug to the patient's current regimen, and 79% of providers would adjust current treatment.
With regard to the usefulness of germline test results, 60% of providers (24 of 40 providers) indicated that they would use this information to tailor treatments (Table 3) . However, providers who indicated confidence in interpreting germline test results were not found to be significantly more likely than their nonconfident colleagues to indicate they would use germline test results to tailor treatment. Providers who indicated that they would use germline results (24 providers) were asked follow-up questions around this use and 67% reported they would use the germline test results to find a new study for the patient, 63% would add a specific drug to the patient's current regimen, and 88% would adjust current treatment. We elicited provider preferences regarding the data elements they prefer to accompany CGES reports (see Supporting Information Table 1 ). The strongest preference for somatic reports was information regarding variant actionability (75%) and a description of the genes altered with associated medical conditions (67%) on germline reports. No significant differences with regard to data elements were observed based on level of training or provider confidence.
Perceived Risks and Benefits
Providers were asked a series of questions concerning their perceived risks and benefits of patient participation in the upcoming genomic sequencing study Genomes for Kids (Table 4) . Of the potential risks, psychosocial impact was of concern for 73% of providers, followed by concern for loss of insurability for 46%, and concern for impact on privacy or confidentiality for 35%. Of the potential benefits, surveillance for and early treatment of secondary cancers (both for the enrolled pediatric oncology patient and for other family members) was indicated to be of importance to 75% of providers. Approximately 69% of providers indicated that CGES information would be beneficial in understanding cancer risk in the family and 60% stated a benefit in identifying the cause of the patient's cancer. No significant differences were observed based on provider confidence in interpreting CGES.
DISCUSSION
In this survey, we focused on confidence, use, and communication surrounding CGES among pediatric hematology/oncology providers working at an NCCN facility. In other studies, confidence usually is associated with medical oncology, being a researcher, and access to baseline genetic testing 13 ; nevertheless, despite these factors being applicable to the clinical providers surveyed herein, confidence rates were found to be no higher than those reported elsewhere. The results of the current study illustrate that even among this specialized group of pediatric hematology/oncology physicians practicing in an area with an established role for precision medicine initiatives, at least 50% indicated nonconfidence in their ability to interpret, discuss, and use CGES findings. With the recent emphasis on molecular tumor profiling in the oncology community, the low confidence around somatic genomic data was surprising and may represent a potential barrier to the successful translation of somatic genomic data into therapeutic decision making. Given that less than onethird of respondents expressed confidence in all 3 domains around germline CGES, identifying an oncology peer knowledgeable in genomics may be challenging. The current study results indicate that further education is necessary across all physician experience levels (fellow and attending physician) for the purpose of increasing provider confidence around clinical genomics. Pediatric molecular tumor boards may be one venue for efficiently ascribing the pathogenicity and actionability of CGES findings across a diverse base of oncologists. 16 Knowledge of the pathogenicity of genomic variants is being increasingly described, [17] [18] [19] [20] and standards for variant interpretation are evolving. The speed of these changes may make it difficult for clinicians to stay up to date with advances in the field, thereby limiting provider Given the lack of confidence around CGES, it is not surprising that approximately two-thirds of respondents (27 of 40 respondents), regardless of confidence level, desired that a GC be present when germline test findings were conveyed to a patient and family. Nearly all respondents (37 of 40; 93%) reported wishing to speak with a GC prior to the disclosure of test results. These results suggest that a shared-disclosure model may be preferred by many oncologists and highlights the importance of having trained GCs available for both providers and patients.
In recent recommendations from the Clinical Genetics Think Tank (CGTT), experts identified the importance of genomics education and training to provide clinicians with the knowledge base for evaluating the appropriateness of CGES and providing adequate pretest counseling. 21 There may be significant risks of harm when clinicians who are inadequately trained to order, discuss, and evaluate CGES results do so independently.
As an example, patients may be harmed by excess or inadequate screening or treatment as a result of the inappropriate interpretation and application of CGES results, thus violating the ethical principle of nonmaleficence. The CGTT suggested that centers may wish to develop an institutional gatekeeper to review requests for CGES testing and coordinate provider education. 21 At the study institution, this expertise is coordinated by a multidisciplinary team of specialists from oncology, genetics, pathology, computational biology, ethics, nursing research, and psychology. This team supports the interpretation and disclosure of germline CGES results and is available to facilitate reevaluation and communication of revised germline CGES results as variants are reinterpreted over time. Although these services are consistent with many CGTT recommendations, smaller institutions with less expertise and/or resources may find these recommendations difficult to implement. These centers may find value in supporting advanced training for their providers concerning the translation of CGES into patient care and to partner with larger academic centers, perhaps via regularly scheduled video or teleconferencing.
Survey respondents believed in many potential benefits for CGES, in particular that CGES might facilitate the surveillance and early treatment of second cancers/ cancer in the patient or their family. However, this potential benefit must be balanced against current limitations in the understanding of genotype-phenotype relationships, variability in disease penetrance and expression, potential risks of unnecessary screening and treatment, and adverse psychological outcomes related to cancer worry. In fact, the psychological impact of genomic testing was the most commonly endorsed risk (73%) of CGES among respondents, whereas loss of insurability and privacy concerns were risks identified by fewer than one-half of respondents. Parents do not appear to share the same concerns regarding psychological risk, 22 and to the best of our knowledge it is unknown how provider perceptions of risk and benefit influence their conversations with patients around CGES. As a result, this area provides ample opportunity for future research.
The current study was a single-institution investigation of physicians at a pediatric NCCN facility and as such, the findings may not be generalizable to pediatric oncologists practicing elsewhere, although we anticipate that genomic confidence is likely low at other smaller institutions based on findings previously reported among medical oncologists. 13 It also remains uncertain whether expressed self-confidence in understanding and using CGES is indicative of true skill. Another potential limitation involves response bias and limited demographic information regarding survey respondents. Although the response rate in the current study was consistent with other physician surveys, it is possible that nonrespondents may have been more or less comfortable with CGES or represent a certain demographic within this field.
